The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: Protein distribution and the glial response.
暂无分享,去创建一个
M. Mahoney | K. Lampe | K. Bjugstad | D. S. Kern | Kyle J Lampe | Drew S Kern | Melissa J Mahoney | Kimberly B Bjugstad | Drew S. Kern
[1] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[2] Yang D. Teng,et al. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells , 2007, Proceedings of the National Academy of Sciences.
[3] M A Tracy,et al. Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted into the Brain , 1999, Cell transplantation.
[4] S. Wiegand,et al. BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine Neurons , 1996, Experimental Neurology.
[5] Blair R. Leavitt,et al. Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.
[6] M. Mahoney,et al. Impact of lactic acid on cell proliferation and free radical‐induced cell death in monolayer cultures of neural precursor cells , 2009, Biotechnology and bioengineering.
[7] Redmond De. Cellular replacement therapy for Parkinson's disease--where we are today? , 2002 .
[8] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[9] A. Benraiss,et al. Adenoviral Brain-Derived Neurotrophic Factor Induces Both Neostriatal and Olfactory Neuronal Recruitment from Endogenous Progenitor Cells in the Adult Forebrain , 2001, The Journal of Neuroscience.
[10] O. Isacson,et al. Immunophilin Ligands and GDNF Enhance Neurite Branching or Elongation from Developing Dopamine Neurons in Culture , 2000, Experimental Neurology.
[11] G. Siegel,et al. Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain , 2000, Brain Research Reviews.
[12] M. Murer,et al. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease , 2001, Progress in Neurobiology.
[13] D. Kirik,et al. Long‐term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system , 2003, The European journal of neuroscience.
[14] A. Björklund,et al. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. , 1996, Neuroscience.
[15] E. Huang,et al. Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.
[16] M. Shive,et al. Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .
[17] R. Roth,et al. Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non‐human primate after overexpression of GDNF , 2009, The Journal of comparative neurology.
[18] Jeffrey A. Hubbell,et al. Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(.alpha.-hydroxy acid) diacrylate macromers , 1993 .
[19] G. Yancopoulos,et al. Neurotrophic Factor Receptors and Their Signal Transduction Capabilities in Rat Astrocytes , 1994, The European journal of neuroscience.
[20] J. Fawcett,et al. The Time Course of Loss of Dopaminergic Neurons and the Gliotic Reaction Surrounding Grafts of Embryonic Mesencephalon to the Striatum , 1996, Experimental Neurology.
[21] A. Heller,et al. Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic neuronal origin , 1996, Brain Research.
[22] R. Ridley,et al. Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.
[23] E. Tolosa,et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. , 1999, Journal of neuropathology and experimental neurology.
[24] M. Mahoney,et al. Development of porous PEG hydrogels that enable efficient, uniform cell-seeding and permit early neural process extension. , 2009, Acta biomaterialia.
[25] T. Dawson,et al. Diagnosis and treatment of Parkinson disease: molecules to medicine. , 2006, The Journal of clinical investigation.
[26] J. Benoit,et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. , 2004, Biomaterials.
[27] Stephanie J Bryant,et al. In situ forming degradable networks and their application in tissue engineering and drug delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[28] E. Clarkson,et al. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats , 1998, Brain Research.
[29] Erwan Bezard,et al. Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.
[30] Steven A. Johnson,et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease , 1991, Neuron.
[31] M. Mahoney,et al. Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: an analysis of the glial response across space and time. , 2010, Journal of biomedical materials research. Part A.
[32] S. Willerth,et al. Approaches to neural tissue engineering using scaffolds for drug delivery. , 2007, Advanced drug delivery reviews.
[33] M. Sofroniew,et al. Essential protective roles of reactive astrocytes in traumatic brain injury. , 2006, Brain : a journal of neurology.
[34] H. Scharfman,et al. Brain-derived neurotrophic factor. , 2004, Growth factors.
[35] Stanley J. Wiegand,et al. Intraventricular Administration of BDNF Increases the Number of Newly Generated Neurons in the Adult Olfactory Bulb , 1998, Molecular and Cellular Neuroscience.
[36] Robert Langer,et al. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. , 2006, Biomaterials.
[37] J. Benoit,et al. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. , 2001, Journal of neurosurgery.
[38] S. Tzeng,et al. Photopolymerizable nanoarray hydrogels deliver CNTF and promote differentiation of neural stem cells , 2010 .
[39] W. Mark Saltzman,et al. Building drug delivery into tissue engineering design , 2002, Nature Reviews Drug Discovery.
[40] G. Yancopoulos,et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.
[41] W. Saltzman,et al. Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. , 1996, Journal of pharmaceutical sciences.
[42] J. Benoit,et al. Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. , 2007, Biomaterials.
[43] K. Unsicker,et al. TGF‐beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. , 1995, The EMBO journal.
[44] W. Mark Saltzman,et al. Localized Delivery of Proteins in the Brain: Can Transport Be Customized? , 1998, Pharmaceutical Research.
[45] J. Benoit,et al. Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[46] J. de Vellis,et al. Stem cell‐based cell therapy in neurological diseases: A review , 2009, Journal of neuroscience research.
[47] M. Mahoney,et al. Impact of degradable macromer content in a poly(ethylene glycol) hydrogel on neural cell metabolic activity, redox state, proliferation, and differentiation. , 2010, Tissue engineering. Part A.
[48] Philippe Menei,et al. In vitro study of GDNF release from biodegradable PLGA microspheres. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[49] Stanley J. Wiegand,et al. Infusion of Brain-Derived Neurotrophic Factor into the Lateral Ventricle of the Adult Rat Leads to New Neurons in the Parenchyma of the Striatum, Septum, Thalamus, and Hypothalamus , 2001, The Journal of Neuroscience.
[50] J. Zimmer,et al. Effects of Donor Age and Brain-Derived Neurotrophic Factor on the Survival of Dopaminergic Neurons and Axonal Growth in Postnatal Rat Nigrostriatal Cocultures , 1996, Experimental Neurology.
[51] M. Mahoney,et al. Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture. , 2010, Journal of biomedical materials research. Part A.
[52] F. Aloisi. Immune function of microglia , 2001, Glia.
[53] J. Lanciego,et al. Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[54] T. Blunk,et al. Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[55] M. Mahoney,et al. Biocompatibility of PEG-Based Hydrogels in Primate Brain , 2008, Cell transplantation.
[56] J. Benoit,et al. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease , 2004, Neuroscience Letters.
[57] A. Pérez-Bouza,et al. Effect of GDNF on differentiation of cultured ventral mesencephalic dopaminergic and non-dopaminergic calretinin-expressing neurons , 2005, Brain Research.
[58] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[59] Kristi S Anseth,et al. Three-dimensional growth and function of neural tissue in degradable polyethylene glycol hydrogels. , 2006, Biomaterials.
[60] S. Maier,et al. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. , 2006, Neuron glia biology.
[61] P. Brundin,et al. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. , 2006, International journal of pharmaceutics.
[62] Kristi S. Anseth,et al. Predicting Controlled-Release Behavior of Degradable PLA-b-PEG-b-PLA Hydrogels , 2001 .
[63] G. L. Curran,et al. Macromolecular permeability across the blood-nerve and blood-brain barriers , 1994 .